Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into ...

Hope is on the horizon as a new review indicates a growing number of potential treatments for Alzheimer’s disease.. The review, spearheaded by a University of Nevada expert and featured in the ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope.

Dementia is a condition that affects memory, thinking, and behavior, and it tends to get worse over time. While there is ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

A medical breakthrough could soon change how we diagnose one of the most devastating brain diseases of our time. On Bloom, I ...

Kevin Smith, a resident of Clifton Park, is experiencing the benefits of a recently approved Alzheimer's drug, Leqembi, as he ...

The study, published March 6 in Nature Medicine, shows that the brain’s immune cells, called microglia, play a more powerful ...

A team of researchers has discovered that a protein called cypin plays a powerful role in helping brain cells connect and communicate, which is crucial for learning and memory. By uncovering how cypin ...

Register to join Lisa Dent at the 2025 Walk to End Alzheimer’s – Chicago on Saturday, October 4 in Lincoln Park. The Walk ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...